'Circulating Tumour Cells: Biomarker Utility and Insights to Metastasis'

Add to your list(s) Download to your calendar using vCal

• Professor Caroline Dive, Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Manchester
• Tuesday 14 August 2012, 12:00-13:00
• CRI Lecture Theatre.

If you have a question about this talk, please contact Mala Jayasundera.

Tissue biopsies are clearly the gold standard with which to interrogate a patient’s tumour biology and assess biomarkers useful for treatment decision making. However, for longitudinal monitoring of disease in certain cancer types (e.g. lung and pancreas and particularly in patients with multiple metastatic lesions), serial biopsies may not be readily acquired and easily repeatable and a less invasive tumour sample is required. With lung cancer as the main example, this seminar will explore the technology platforms for CTC analysis, the prognostic significance of CTC number, and the potential in early clinical trial settings for CTC assays of predictive biomarkers and for demonstrating proof of drug mechanism and concept. The possibility to examine tumour evolution from a drug sensitive to drug resistant phenotypes via CTC analysis will be discussed given the current paradigms of response followed by relapsed witnessed for several targeted therapeutics. The biology of CTCs with respect to epithelial to mesenchyme transition together with the relevance and composition of circulating tumour microemboli will be also be addressed. Finally, the horizon of profiling CTCs will be touched upon and the biological relevance of CTCs regarding intra-tumour heterogeneity will be debated.

This talk is part of the Cambridge Oncology Seminar Series series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• CCC talks for website
• CRI Lecture Theatre
• Cambridge Oncology Seminar Series
• Life Sciences
• Life Sciences
• cri

Note that ex-directory lists are not shown.